4 quarters tracked · Beat rate 25% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q4 2026 | 2026-03-31 | $-0.35 | $-0.58 | -64.6% | Miss |
| Q3 2026 | 2025-12-31 | $-0.32 | $-0.38 | -17.3% | Miss |
| Q2 2026 | 2025-09-30 | $-0.34 | $-0.17 | +50.1% | Beat |
| Q1 2026 | 2025-06-30 | $-0.32 | $-0.33 | -4.4% | Miss |
Earnings Beat Rate
Roivant Sciences has beaten analyst EPS estimates in 1 of 4 tracked quarters (25% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →